SLC5A2 and diabetes mellitus: Utilizing integrated bioinformatic, in vivo, and in vitro approaches, we have revealed the inflammatory profile of the chronically diseased kidney in diabetes and how SGLT2 inhibitor dapagliflozin could ameliorate DKD.